Updated on 8 June 2012
Anti-plated medicine Plavix, which is jointly marketed by Bristol-Myers Squibb (BMS) and Sanofi-aventis, is used to treat acute coronary syndrome in patients who are managed medically or through coronary revascularization. The drug has been shown to decrease the rate of cardiovascular death, myocardial infarction, stroke or refractory ischemia.
China continued to be the major revenue earner for Plavix with sales revenue of $253 million in 2011, followed by Thailand with sales figure of $30 million. Hong Kong, Korea, Malaysia, Taiwan, and Vietnam are the other prime markets for Plavix, together accounting for a revenue of $146 million in 2011. Plavix is also the only non-local product that figured in the top 10 list of products in China.
Other products that made it to the top 10 products ranking include AstraZeneca's Nexium, GlaxoSmithKline's Seretide, BMS' Baraclude, Genentech's Lucentis and Herceptin, Eli Lilly's Zyprexa, and Novartis' Glivec. All the top 10 pharma products in the Asia Pacific region boasted of a combined revenue of $98.3 billion in 2011, registering a growth rate of 12.1 percent over 2010.
Baraclude, a medicine for Hepatitis B, claimed the top spot in the Korean market. Hep B is one of the most common serious liver infections in the world and affects a large part of the Korean population. India, which has one of the largest patient pools, saw local products doing well.
Top 10 pharma therapies
Cephalosporins and Combs continued to maintain its lead in the pharma therapies domain with revenue worth $6.5 billion in 2011 as compared to $6.2 billion in 2010 and $5.2 billion in 2009. Other therapies that made it to the top 10 list included Kanpo and Chinese medicines (with the revenue of $4.7 billion and growth rate of 24.4 percent), anti-ulcerants (revenue $3.4 billion, growth rate 13.1 percent), cholesterol and triglycerides regulator (revenue $2.8 billion, growth rate 8.9 percent), all other anti-neoplastics (revenue $2.3 billion, growth rate 17.9 percent), broad spectrum penicillin (revenue $2.1 billion, growth rate 1.2 percent), Cerebral and Peripheral Vasotherapy (revenue $2 billion, growth rate 18.9 percent), Standard solutions (revenue $1.5 billion, growth rate 10.5 percent), anti-rheumatic N-steroid (revenue $1.5 billion, growth rate 7.6 percent) and platelet inhibitors (revenue $1.5 billion, growth rate 7.1 percent). The top 10 therapies generated revenue of $28.8 billion in 2011 as compared to $25 billion and $20 billion in 2010 and 2009, respectively.